2025
Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy
Oikonomou E, Sangha V, Vasisht Shankar S, Coppi A, Krumholz H, Nasir K, Miller E, Gallegos Kattan C, Al-Mallah M, Al-Kindi S, Khera R. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy. European Heart Journal 2025, ehaf450. PMID: 40679604, DOI: 10.1093/eurheartj/ehaf450.Peer-Reviewed Original ResearchTransthyretin amyloid cardiomyopathyTransthoracic echocardiographyATTR-CMAmyloid cardiomyopathyPreclinical progressAI-ECGRetrospective analysisDiagnosis of transthyretin amyloid cardiomyopathyDeep learning modelsAge/sex matched controlsRetrospective analysis of individualsLearning modelsPreclinical testingElectrocardiography imagingEchocardiographyHouston Methodist HospitalYale New Haven Health SystemAdvanced imagingElectrocardiographyPreclinical coursesCardiomyopathyPreclinical stage
2012
Appropriate And Inappropriate Imaging Rates For Prostate Cancer Go Hand In Hand By Region, As If Set By Thermostat
Makarov DV, Desai R, Yu JB, Sharma R, Abraham N, Albertsen PC, Krumholz HM, Penson DF, Gross CP. Appropriate And Inappropriate Imaging Rates For Prostate Cancer Go Hand In Hand By Region, As If Set By Thermostat. Health Affairs 2012, 31: 730-740. PMID: 22492890, DOI: 10.1377/hlthaff.2011.0336.Peer-Reviewed Original ResearchConceptsInappropriate imagingAppropriate imagingProstate cancerHigh-risk prostate cancerHigh rateHigh-risk patientsHealth care utilizationProstate cancer patientsCross-sectional studyOverall imaging rateHealth care costsLower ratesCare utilizationCancer patientsAppropriate treatmentAdvanced imagingCare costsPatientsHealth care organizationsCare organizationsCancerCost containmentImagingImaging rateRegional variation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply